Citigroup Forecasts Strong Price Appreciation for Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective lifted by investment analysts at Citigroup from $9.00 to $13.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “sell” rating on the biotechnology company’s stock. Citigroup’s price objective indicates a potential downside of 34.90% from the stock’s current price.

Several other analysts have also commented on SRPT. Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a research report on Tuesday, March 3rd. Oppenheimer reissued an “outperform” rating and set a $37.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Jefferies Financial Group restated a “buy” rating and issued a $30.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. Finally, HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a report on Monday, March 2nd. Nine equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $32.30.

Sarepta Therapeutics Trading Down 7.9%

Shares of SRPT opened at $19.97 on Thursday. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $72.05. The firm has a market capitalization of $2.10 billion, a P/E ratio of -2.37, a P/E/G ratio of 0.34 and a beta of 0.42. The firm has a 50-day moving average price of $18.69 and a 200 day moving average price of $19.99. The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The firm had revenue of $442.93 million for the quarter, compared to analysts’ expectations of $390.95 million. During the same period last year, the firm earned $1.90 earnings per share. Sarepta Therapeutics’s revenue for the quarter was down 32.7% on a year-over-year basis. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Activity

In other news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the sale, the director owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC acquired a new stake in Sarepta Therapeutics during the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd acquired a new position in shares of Sarepta Therapeutics in the third quarter worth $25,000. Ancora Advisors LLC increased its position in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the period. Byrne Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth $33,000. Finally, Allworth Financial LP raised its stake in shares of Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early siRNA Phase 1/2 data (SRP‑1001, SRP‑1003) impressed investors — strong target knockdown, safety and muscle delivery signals sparked the share rally and lifted sentiment on Sarepta. SRPT Stock Surges on Promising Early Results From siRNA Programs
• Positive Sentiment: Options flow has been very bullish — large volume of call purchases suggests traders are positioning for further upside or continued momentum. Investors Buy Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT)
• Positive Sentiment: At least one major shop (reported coverage) raised its price target after the data, which helped validate the clinical news and contributed to the rally. Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results
• Neutral Sentiment: Analyst consensus remains cautious/neutral overall — the stock’s average rating is a “Hold,” reflecting mixed views despite the clinical upside. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of “Hold” from Brokerages
• Neutral Sentiment: Valuation and longer‑term upside are being reassessed: several writeups model potential upside but note the one‑day rebound and remaining execution risks. Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results
• Negative Sentiment: Some sell/underperform stances persist — Citigroup raised its PT but kept a sell rating, and Needham reaffirmed underperform, highlighting continued skepticism among parts of the sell‑side. These views can cap rallies if the broader data set or guidance don’t follow through. Brokerage Notes (Citigroup/Needham)
• Negative Sentiment: Cautious takeaways from analysts/commentators emphasize the data are early and limited; some warn it’s too soon to extrapolate material commercial potential, which could lead to profit‑taking or volatility. Sarepta Therapeutics: It’s Too Early To Get Excited About siRNA Data

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.